Oncologic and Functional Outcomes of Salvage Cryotherapy in Prostate Cancer: Single Center Experience from a Referral Center in Spain
SIU Academy®. GUTIERREZ A. 11/12/21; 342337; UP-16.121 Topic: Focal therapy
Mr. ANDRES GUTIERREZ
Mr. ANDRES GUTIERREZ
Contributions Biography
Abstract
Oncologic and Functional Outcomes of Salvage Cryotherapy in Prostate Cancer: Single Center Experience from a Referral Center in Spain

Topic: Prostate Cancer

Applicant 1: Andrés, Applicant 2: Claudia, Applicant 3: Joan, Applicant 4: Mireia, Applicant 5: Agustin, Applicant 6: Maria Jose, Applicant 7: Antonio, Applicant 8: Sandra, Applicant 9: Enrique, Applicant 10: Nicolas, Applicant 11: Jesus

Applicant 1: Gutiérrez, Applicant 2: Mercader, Applicant 3: Sureda, Applicant 4: Musquera, Applicant 5: Franco, Applicant 6: Ribal, Applicant 7: Alcaraz, Applicant 8: Jorcano, Applicant 9: Gallardo, Applicant 10: Feltes, Applicant 11: Muñoz

Applicant 1: Urology Department, Hospital Clínic de Barcelona, Applicant 2: Urology Department, Hospital Clínic de Barcelona, Applicant 3: Urology Department, Hospital Clínic de Barcelona, Applicant 4: Urology Department, Hospital Clínic de Barcelona, Applicant 5: Urology Department, Hospital Clínic de Barcelona, Applicant 6: Urology Department, Hospital Clínic de Barcelona, Applicant 7: Urology Department, Hospital Clínic de Barcelona, Applicant 8: Radiation Oncology Department, Hospital Clínic de Barcelona, Applicant 9: Medical Oncology Department, Parc Taulí University Hospital, The Parc Taulí Research and Innovation Institute (I3PT), Universitat Autònoma de Barcelona, Applicant 10: Radiation Oncology, Hospital de Terrassa, Applicant 11: Urology Department, Parc Taulí University Hospital, The Parc Taulí Research and Innovation Institute (I3PT), Universitat Autònoma de Barcelona

Applicant 1: Spain, Applicant 2: Spain, Applicant 3: Spain, Applicant 4: Spain, Applicant 5: Spain, Applicant 6: Spain, Applicant 7: Spain, Applicant 8: Spain, Applicant 9: Spain, Applicant 10: Spain, Applicant 11: Spain

Applicant 1: Presenting Author, Applicant 2: Author/Co-Author, Applicant 3: Author/Co-Author, Applicant 4: Author/Co-Author, Applicant 5: Author/Co-Author, Applicant 6: Author/Co-Author, Applicant 7: Author/Co-Author, Applicant 8: Author/Co-Author, Applicant 9: Author/Co-Author, Applicant 10: Author/Co-Author, Applicant 11: Author/Co-Author

Introduction and Objectives: Salvage cryotherapy (SC) is a treatment option with curative intention for localized prostate cancer (PC) presenting biochemical recurrence (BCR) after failure radical non-surgical treatment. The aim of this study is to evaluate oncological and functional outcomes of SC in a referral hospital in Spain.Materials and Methods:

We reviewed all patients who underwent SC between January 2008 and December 2018. Primary endpoint was biochemical progression-free survival (BPFS) defined by Phoenix criteria. Secondary endpoints were overall survival (OS), cancer-specific survival (CSS), patient reported functional outcomes and complications.

Results:

In total, 54 patients underwent SC. The mean age at BCR of the primary treatment was 71.5 years. External beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) was the most frequent initial treatment in 50%, followed by primary cryotherapy (29.63%). Median follow-up after SC was 42 months. Overall BPFS was 69.3% with a median time of 97 months (Fig.1A). There was a significant difference among the low, intermediate and high D\'Amico risk group and BPFS. 2 and 5-year overall BPFS was 93.5% and 74.2%. OS at 2 and 5-year, was 72.2% and 29.6%, while CSS at 2 and 5-year was 100% and 71,4%. Multivariate analysis showed that PSA at BCR after primary treatment (HR 0.36), PSA nadir after SC (HR 1.35) and PSA nadir >0.5 ng/mL after SC (HR 4.39) were associated with time to BCR after SC (Fig.1B). Complications were urinary tract infection (27.77%), acute urinary retention (14.81%) and urethral stenosis (11.11%). No fistulas were reported. Mild urinary incontinence (UI) was reported in 7.4%, while 9.2% presented greater UI.

Conclusion: In our series, SC for prostate cancer patients offers good oncological and functional outcomes with minimal complications. PSA at BCR after primary treatment, PSA nadir after SC and PSA nadir >0.5 ng/mL after SC, were associated with time to BCR after SC in the multivariate analysis.
Oncologic and Functional Outcomes of Salvage Cryotherapy in Prostate Cancer: Single Center Experience from a Referral Center in Spain

Topic: Prostate Cancer

Applicant 1: Andrés, Applicant 2: Claudia, Applicant 3: Joan, Applicant 4: Mireia, Applicant 5: Agustin, Applicant 6: Maria Jose, Applicant 7: Antonio, Applicant 8: Sandra, Applicant 9: Enrique, Applicant 10: Nicolas, Applicant 11: Jesus

Applicant 1: Gutiérrez, Applicant 2: Mercader, Applicant 3: Sureda, Applicant 4: Musquera, Applicant 5: Franco, Applicant 6: Ribal, Applicant 7: Alcaraz, Applicant 8: Jorcano, Applicant 9: Gallardo, Applicant 10: Feltes, Applicant 11: Muñoz

Applicant 1: Urology Department, Hospital Clínic de Barcelona, Applicant 2: Urology Department, Hospital Clínic de Barcelona, Applicant 3: Urology Department, Hospital Clínic de Barcelona, Applicant 4: Urology Department, Hospital Clínic de Barcelona, Applicant 5: Urology Department, Hospital Clínic de Barcelona, Applicant 6: Urology Department, Hospital Clínic de Barcelona, Applicant 7: Urology Department, Hospital Clínic de Barcelona, Applicant 8: Radiation Oncology Department, Hospital Clínic de Barcelona, Applicant 9: Medical Oncology Department, Parc Taulí University Hospital, The Parc Taulí Research and Innovation Institute (I3PT), Universitat Autònoma de Barcelona, Applicant 10: Radiation Oncology, Hospital de Terrassa, Applicant 11: Urology Department, Parc Taulí University Hospital, The Parc Taulí Research and Innovation Institute (I3PT), Universitat Autònoma de Barcelona

Applicant 1: Spain, Applicant 2: Spain, Applicant 3: Spain, Applicant 4: Spain, Applicant 5: Spain, Applicant 6: Spain, Applicant 7: Spain, Applicant 8: Spain, Applicant 9: Spain, Applicant 10: Spain, Applicant 11: Spain

Applicant 1: Presenting Author, Applicant 2: Author/Co-Author, Applicant 3: Author/Co-Author, Applicant 4: Author/Co-Author, Applicant 5: Author/Co-Author, Applicant 6: Author/Co-Author, Applicant 7: Author/Co-Author, Applicant 8: Author/Co-Author, Applicant 9: Author/Co-Author, Applicant 10: Author/Co-Author, Applicant 11: Author/Co-Author

Introduction and Objectives: Salvage cryotherapy (SC) is a treatment option with curative intention for localized prostate cancer (PC) presenting biochemical recurrence (BCR) after failure radical non-surgical treatment. The aim of this study is to evaluate oncological and functional outcomes of SC in a referral hospital in Spain.Materials and Methods:

We reviewed all patients who underwent SC between January 2008 and December 2018. Primary endpoint was biochemical progression-free survival (BPFS) defined by Phoenix criteria. Secondary endpoints were overall survival (OS), cancer-specific survival (CSS), patient reported functional outcomes and complications.

Results:

In total, 54 patients underwent SC. The mean age at BCR of the primary treatment was 71.5 years. External beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) was the most frequent initial treatment in 50%, followed by primary cryotherapy (29.63%). Median follow-up after SC was 42 months. Overall BPFS was 69.3% with a median time of 97 months (Fig.1A). There was a significant difference among the low, intermediate and high D\'Amico risk group and BPFS. 2 and 5-year overall BPFS was 93.5% and 74.2%. OS at 2 and 5-year, was 72.2% and 29.6%, while CSS at 2 and 5-year was 100% and 71,4%. Multivariate analysis showed that PSA at BCR after primary treatment (HR 0.36), PSA nadir after SC (HR 1.35) and PSA nadir >0.5 ng/mL after SC (HR 4.39) were associated with time to BCR after SC (Fig.1B). Complications were urinary tract infection (27.77%), acute urinary retention (14.81%) and urethral stenosis (11.11%). No fistulas were reported. Mild urinary incontinence (UI) was reported in 7.4%, while 9.2% presented greater UI.

Conclusion: In our series, SC for prostate cancer patients offers good oncological and functional outcomes with minimal complications. PSA at BCR after primary treatment, PSA nadir after SC and PSA nadir >0.5 ng/mL after SC, were associated with time to BCR after SC in the multivariate analysis.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies